Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

U.S. health officials are asking retailers to pull a small number of acne creams from their store shelves after government testing found they contain slightly elevated levels ...

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...

DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a ...

Kohl's Corp forecast a bigger drop in annual comparable sales than expected on Tuesday, piling on more pressure on new boss ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Earn $+0.06 per options contract and 5.1% APY on cash with no restrictions ... clinical trials of the company's obesity drug, which came with Roche's $2.7 billion purchase of drugmaker Carmot ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market seg ...

European markets are heading for a sharply higher open amid hopes that a ceasefire can be reached to pause the war in Ukraine.